|
| |
 |
| BRIEF COMMUNICATION |
|
| Year : 2016 | Volume
: 20
| Issue : 3 | Page : 408-411 |
|
Flexibility in insulin prescription
Sanjay Kalra1, Yashdeep Gupta2, Ambika Gopalakrishnan Unnikrishnan3
1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India
3 Department of Endocrinology, Chellaram Diabetes Institute, Pune, Maharashtra, India
| Date of Web Publication | 11-Apr-2016 |
Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.180003
 Abstract | | |
This communication explores the concept of flexibility, a propos insulin preparations and insulin regimes used in the management of type 2 diabetes. The flexibility of an insulin regime or preparation is defined as their ability to be injected at variable times, with variable injection-meal time gaps, in a dose frequency and quantum determined by shared decision making, with a minimal requirement of glucose monitoring and health professional consultation, with no compromise on safety, efficiency and tolerability. The relative flexibility of various basal, prandial and dual action insulins, as well as intensive regimes, is compared. The biopsychosocial model of health is used to assess the utility of different insulins while encouraging a philosophy of flexible insulin usage. Keywords: Biphasic aspart, biphasic lispro, degludec, degludec aspart, detemir, glargine, glulisine, hypoglycemia, insulin aspart, lispro, neutral protamine Hagedorn, type 2 diabetes
How to cite this article:
Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocr Metab 2016;20:408-11 |
| Introduction | |  |
“DO NOT match lifestyle to the insulin regimens. RATHER, match the regimen to the lifestyle” Easier said than done, this statement reflects the core philosophy of person-centered care. Keeping the person with diabetes at center stage of treatment, one should try to provide effective, safe glycemic control, with minimal intrusion into his or her lifestyle. Traditional insulin regimes, such as human insulin based protocols, and basal-bolus therapy may demand strict observation of 3 + 3 meal patterns, and require insulin administration at specified times of the day. The rigidity which characterizes these treatments prevents the practice of person-centered care in the true sense.
Development of newer insulins and insulin co-formulations has introduced the concept of flexibility in diabetes care.
Flexibility is an adjective which describes the capability of a material, schedule, or personality to bend, adapt or yield.[1] A flexible ruler, for example, can easily be bent without breaking. A flexible agenda is one which can be modified or adapted while a flexible person demonstrates pliability or is agreeable to change. In medicine, flexibility may be taken to mean the absolute range of movement at a joint(s).[2] This concept also incorporates the change in muscle length.
In diabetes care, the word flexibility can be used to qualify treatment targets, treatment regimes, and specific drugs. Flexibility (or the lack thereof) is also an important attribute of persons with diabetes, their caregivers, and diabetes care professionals (DCPs)!
Because of the versatility of this word, it can be used in multiple ways. At the same time, this property makes it susceptible to misuse and confusion. We try to bring clarity to this field by focusing on the flexibility of various insulin regimes and preparations.
Flexibility of an insulin regime and of preparations includes various domains under its umbrella. There include the ability to change time of administration, injection-meal time gaps, site of administration, the number of doses, and quantity of doses from a patient-centre perspective. It also encompasses the intrusion index of insulin therapy, i.e., the need to adhere to strict dietary and physical activity plan, the recommendation frequency of self-monitoring of blood glucose, and the the requirement for other investigation/concomitant treatment modalities. Within particular insulin regimes, flexibility also means the ability to modify specific doses of prandial and basal components.
These domains, though usually concordant with each other, sometimes pose a dilemma for the DCP. What may seem flexibility to the person with diabetes, e.g., the ability to take two premixed instead of four basal-bolus injections, may be thought of as inflexibility by the DCP, who is unable to titrate the ratio of prandial and bolus insulin. Keeping this in mind, a comprehensive definition of flexibility should be aimed at.
We suggest that “flexibility of an insulin regime or preparation is defined as their ability to be injected at variable times, with variable injection-meal time gaps, in a dose frequency and quantum determined by shared decision making, with minimal requirement of glucose monitoring and health professional consultation, with no compromise on safety, efficiency and tolerability.”
The following sections describe various regimes and preparations, focusing on their flexibility, as defined above.
| Insulin Regimes | | |
Conventionally, insulin regimes are classified as basal, premixed, and intensive.[3] An intensive regime is one which includes 3 or more injections per day. Thus, prandial, basal plus (≥3 doses), and basal-bolus regimes are included in the intensive category. Basal plus (2 doses), split-mix, and coformulations are other types of insulin regimes and preparations. Recently, a number-based taxonomy approach has been used to provide a framework which can include both traditional as well as newly developed insulin regimes.[4]
| Basal Insulins | | |
Basal insulin regimes are considered to be simple, less intrusive and flexible, as they involve only one injection per day, do not require adherence to a strict meal pattern, and allow relative freedom of lifestyle.[5] Though neutral protamine Hagedorn insulin should preferably be taken with a snack, basal analogues can be injected without regards to meal timings.
Within the basal insulins, detemir has to be prescribed in the evening or at bedtime, at the same time.[6] Glargine can be injected at any time of the day, at the same time each day.[7] Insulin degludec can be injected at any time of the day, without regards to the previous injection timing, provided an 8 h gap is maintained.[8] Thus, of the basal preparations, glargine and degludec appear the most flexible [Table 1].
| Prandial Insulins | | |
Human regular insulin should be administered 30 min before a meal, while rapid-acting insulin analogues such as aspart, glulisine and aspart offer the advantage of a shorter injection-meal gap. These analogues can be injected 5 min before, or after, a meal, with no negative impact on efficacy.[3]
| Dual Action Insulins | | |
While human premixed insulins (biphasic human insulin) need to be injected 30 min before a meal, premixed insulin analogs (biphasic aspart, biphasic lispro) can be taken 5 min before a meal, or immediately after it.[9] The injections have to be taken with the same meal (s) every day, whether in a once daily, twice daily or thrice daily dose.[4] Insulin co-formulations such as I Deg Asp (insulin degludec aspart) offer the flexibility of change in timing of administration. For example, a person on a once daily regime of I Deg Asp, to be taken with the major meal, may choose to have his injection at breakfast on one day, and at lunch or dinner on the next. A minimum inter-dose gap of 8 h, required, however.[10]
Dual action insulins, including premixed insulins, are relatively less complex as compared to basal-bolus regimes. However, they are limited in flexibility in terms of dose titration, especially self-titration.[11] As with basic algorithms, however, one can easily master the simple skills required to use premixed insulins in a flexible manner.
| The Biopsychosocial Perspective | | |
Flexibility is much more than a semantic term, a pharmacological attribute or a biomedical benchmark. Flexibility is a concept which encompasses the biological, psychological, and social aspects of diabetes care [Box 1]. The unique pharmacological properties of insulin analogues allow subtle differentiation in terms of flexibility and facilitate appropriate choice based on biomedical factors. Personal preferences regarding frequency and timing of administration, as well as the frequency of glucose monitoring, which also play a role in the choice of insulin, are guided by flexibility as well. Social environmental factors, such as nature of the job (involving shift work), availability of privacy for monitoring and injection at specific times, and financial issues, also revolve around flexibility.
Thus, flexibility of insulin straddles the biopsychosocial model of health care. Flexibility is a person-centred concept as well, as it keeps the person's preferences, wishes and needs at centre stage. In large studies, people living with diabetes have highlighted various limiting factors in their management of diabetes, and the need for greater self-involvement. Similar feelings are echoed by their family members and health care professionals. As flexibility responds to patient needs and convenience, it is concordant with the tenants of person-centred care.
| Summary | | |
Discussion and debate around the flexibility of insulin preparations, and insulin regimes, is an important facet of enhancing person-centeredness. The practice of “flexible” treatment regimes, to the extent possible, without harming patient well-being, is a philosophy which mirrors those of person-centred care and the biopsychosocial model. Prescription of drugs which allow flexibility in their use will help achieve the aims of these useful management frameworks.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | | |
| 1. | |
| 2. | Gajdosik RL. Flexibility or muscle length? Phys Ther 1995;75:238-9.  [ PUBMED] |
| 3. | Kalra B, Kalra S. Choosing an insulin analogue regime. Internet J Geriatr Gerontol 2009;5. Available from: https://www.ispub.com/IJGG/5/2/11006. [Last accessed on 2015 Nov 10]. |
| 4. | Kalra S, Gupta Y. Number-based approach to insulin taxonomy. Diabetes Ther 2015;6:469-79. |
| 5. | Kalra S. Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made? Indian J Endocrinol Metab 2015;19 Suppl 1:S71-3. |
| 6. | |
| 7. | |
| 8. | Kalra S, Gupta Y. Clinical use of insulin degludec: Practical experience and pragmatic suggestions. N Am J Med Sci 2015;7:81-5. |
| 9. | Bilotta F, Guerra C, Badenes R, Lolli S, Rosa G. Short acting insulin analogues in intensive care unit patients. World J Diabetes 2014;5:230-4. |
| 10. | Kalra S. Insulin degludec aspart: The first co-formulation of insulin analogues. Diabetes Ther 2014;5:65-72. |
| 11. | Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9. |
[Table 1]
| This article has been cited by | | 1 |
Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel |
|
| Manoj Chawla,Sunil M. Jain,Jothydev Kesavadev,Brij M. Makkar,Vijay Viswanathan,Mangesh Tiwaskar,Aravind R. Sosale,Vijay Negalur,Kirtikumar D. Modi,Mukulesh Gupta,Surinder Kumar,Santosh Ramakrishnan,Nilakshi Deka,Nirmalya Roy | | Diabetes Therapy. 2020; | | [Pubmed] | [DOI] | | | 2 |
Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence |
|
| Jeongmin Lee,Tong Min Kim,Hyunah Kim,Seung-Hwan Lee,Jae Hyoung Cho,Hyunyong Lee,Hyeon Woo Yim,Kun-Ho Yoon,Hun-Sung Kim | | Diabetes & Metabolism Journal. 2020; 44 | | [Pubmed] | [DOI] | | | 3 |
BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion |
|
| Sarita Bajaj,A. K. Das,Sanjay Kalra,Rakesh Sahay,Banshi Saboo,Sambit Das,M. Shunmugavelu,Jubbin Jacob,Gagan Priya,Deepak Khandelwal,Deep Dutta,Manoj Chawla,Vineet Surana,Mangesh Tiwaskar,Ameya Joshi,Pradip Krishna Shrestha,Jyoti Bhattarai,Bishwajit Bhowmik,Tint Swe Latt,Than Than Aye,G. Vijayakumar,Manash Baruah,Fatema Jawad,A. G. Unnikrishnan,Subhankar Chowdhury,Md. Faruqe Pathan,Noel Somasundaram,Manilka Sumanathilaka,Abbas Raza,Silver K. Bahendeka,Ankia Coetzee,Sundeep Ruder,Kaushik Ramaiya,Roberta Lamptey,Charlotte Bavuma,Khalid Shaikh,Andrew Uloko,Sandeep Chaudhary,Abdurezak Ahmed Abdela,Zhanay Akanov,Joel Rodrìguez-Saldaña,Raquel Faradji,Armindo Tiago,Ahmed Reja,Leszek Czupryniak | | Diabetes Therapy. 2019; | | [Pubmed] | [DOI] | | | 4 |
Clinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports |
|
| Nandu Thalange,Torben Biester,Thomas Danne | | Diabetes Therapy. 2019; 10(4): 1219 | | [Pubmed] | [DOI] | | | 5 |
Patient-centered Choice of Prandial Insulin |
|
| Sanjay Kalra,Vishal Bhatia,Nikhil Gupta,Feroz Amin,AG Unnikrishnan | | US Endocrinology. 2019; 15(1): 20 | | [Pubmed] | [DOI] | | | 6 |
Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility |
|
| Sanjay Kalra,Deepak Khandelwal | | European Endocrinology. 2018; 14(2): 20 | | [Pubmed] | [DOI] | | | 7 |
Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus |
|
| Nabil El Naggar,Sanjay Kalra | | Advances in Therapy. 2017; 33(12): 2091 | | [Pubmed] | [DOI] | |
|
 |
|
|
|
